Natera: Capitalizing On The Positive Momentum Of Personalized Medicine

Since inception, Natera (NASDAQ:NTRA) has incurred sustained losses, with their cash burn rate being one of the largest concerns to investors. However, the company seems to be on the verge of becoming profitable for the first time in its history. In my opinion, this is mostly due to the growth of the personalised medicines, particularly in oncology, together with the recently approved biomarkers law in 13 U.S. states. Thus, I consider that Natera as a “buy,” despite the risks associated with it. Personalise ...